Immunologic Factors: all 3,292 studies that test it
Page 26 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) ExacerbationWithdrawnNCT01151735Phase 4
- Attenuating Ischemia Reperfusion Injury After Living Donor Renal TransplantationWithdrawnNCT01149993Phase 4
- Interferon Alpha Lozenges Plus Oseltamivir for Influenza TreatmentCompletedNCT01146535Phase 2
- Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal TransplantationCompletedNCT01136395Phase 2
- Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)CompletedNCT01135641Phase 2
- Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaCompletedNCT01134432Phase 3
- Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic LeukemiaCompletedNCT01133743Phase 2
- Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell LymphomaStatus unknownNCT01132989Phase 2
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
- Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic AnemiaWithdrawnNCT01129323Not applicable
- Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First LineStatus unknownNCT01127841Phase 2
- RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) TrialTerminatedNCT01127542Phase 2
- Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia SyndromeCompletedNCT01127386Phase 1/2
- Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal CancerTerminatedNCT01126450Phase 1
- Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) LymphomaCompletedNCT01124526Phase 4
- Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOPCompletedNCT01122472Phase 3
- Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)CompletedNCT01118234Phase 3
- Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant PatientsTerminatedNCT01117662Phase 3
- A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)TerminatedNCT01117129Phase 4
- Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic LeukemiaCompletedNCT01116193Phase 2
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late RelapseCompletedNCT01111903Phase 1/2
- Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITPCompletedNCT01107951Phase 2
- Rituximab Maintenance After Autologous TransplantationTerminatedNCT01103388Phase 3
- Lenalidomide Maintenance Post-debulking in Advanced CTCLTerminatedNCT01098656Phase 3
- RituxiMab INDuction in Renal TransplantationStatus unknownNCT01095172Phase 4
- Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsCompletedNCT01093196Phase 3
- Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01091831Phase 3
- Combination of Lenalidomide and Dexamethasone in Treatment of Multiple MyelomaCompletedNCT01090089Phase 3
- Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)CompletedNCT01088724Phase 4
- A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)CompletedNCT01087151Phase 2
- Rituximab for Autoimmune RetinopathyCompletedNCT01086631Phase 1
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01085617
- Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5qCompletedNCT01081431Phase 2
- Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT01078142Phase 1/2
- Natalizumab Treatment of Progressive Multiple SclerosisCompletedNCT01077466Phase 2
- Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT01076556Phase 1
- Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal TransplantationStatus unknownNCT01066689Phase 3
- A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT01066598Phase 2
- Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01062152Phase 1
- Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon CancerCompletedNCT01060501Phase 3
- Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma PatientsCompletedNCT01056679Phase 1
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
- S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT01055301Phase 2
- Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01054781Phase 2
- IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaCompletedNCT01053949Phase 2
- Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic SyndromeStatus unknownNCT01053806Phase 2
- Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal TransplantationCompletedNCT01046955Phase 4
- Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaCompletedNCT01046006Phase 2
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple MyelomaCompletedNCT01042704Phase 1
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) PatientsTerminatedNCT01036399Phase 2
- Rituximab in Metastatic MelanomaTerminatedNCT01032122Phase 1
- mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal TransplantationCompletedNCT01028092Phase 3
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With BendamustineCompletedNCT01022021Early Phase 1
- Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic TherapyCompletedNCT01021735Phase 4
- Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT01020734Phase 2
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesCompletedNCT01019876Phase 2/3
- Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT01017159Phase 2
- Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT01015248Phase 2
- Third-line Therapy of Multiple Myeloma a Prospective Phase I /II TrialStatus unknownNCT01010243Phase 1/2
- Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's LymphomaStatus unknownNCT01009970Phase 2
- A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior TreatmentCompletedNCT01007292Phase 2
- A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)TerminatedNCT01005979Phase 1
- Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01002703Phase 1/2
- Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host DiseaseWithdrawnNCT01001780Phase 2
- Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected AdultsStatus unknownNCT00999739Phase 3
- Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaCompletedNCT00992134Phase 2
- R-ABVD vs ABVD-RT in Early Stage Hodgkin's LymphomaTerminatedNCT00992030Phase 3
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaCompletedNCT00987493Phase 1/2
- Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT00981838Phase 3
- Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)CompletedNCT00981708Phase 1/2
- R Retreatment in 1st Relapsed DLBCLStatus unknownNCT00980304Phase 2
- Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic SyndromeTerminatedNCT00977132Phase 2
- Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaStatus unknownNCT00974792Phase 2
- Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous LeishmaniasisCompletedNCT00973128Phase 2
- Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)TerminatedNCT00972842Phase 1/2
- Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00971763Phase 2
- The Treatment of Lenalidomide in Patients With POEMS SyndromeStatus unknownNCT00971685Phase 2
- Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT00968331Phase 2
- High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell LymphomaCompletedNCT00965289Phase 2
- Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid ArthritisCompletedNCT00963703Not applicable
- Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.CompletedNCT00963534Phase 1/2
- RMPT for Relapsed/Refractory Multiple MyelomaCompletedNCT00961467Phase 2
- Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
- Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent LymphomaTerminatedNCT00954005Phase 1/2
- Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic StageCompletedNCT00949364Phase 2
- Intravenous Immunoglobulins in Complex-regional Pain SyndromeWithdrawnNCT00949065Phase 3
- Biomarkers and Response to Natalizumab for Multiple Sclerosis TreatmentCompletedNCT00942214Phase 4
- S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00939328Phase 2
- A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyCompletedNCT00936546Phase 2
- Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell TransplantationStatus unknownNCT00934557Phase 3
- Lenalidomide and Paclitaxel in Prostate CancerTerminatedNCT00933426Phase 1
- A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular LymphomaCompletedNCT00930514Phase 1
- Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)Status unknownNCT00927797Phase 2
- Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) TypeStatus unknownNCT00923663Phase 2
- Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
- Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceCompletedNCT00921414Phase 3